Form 4: Merit Medical Executive Chairman Sells 5,000 Shares

Merit Medical Systems' Executive Chairman, Fred P. Lampropoulos, reported the sale of 5,000 shares of common stock at a weighted average price of $84.826 per share.

Summary

• Fred P. Lampropoulos, Executive Chairman and Director of Merit Medical Systems Inc. (MMSI), reported a sale of common stock.
• On November 18, 2025, Mr. Lampropoulos disposed of 5,000 shares of MMSI common stock.
• The shares were sold at a weighted average price of $84.826 per share, with individual transactions ranging from $84.03 to $86.44.
• Following this transaction, Mr. Lampropoulos directly beneficially owns 1,074,955 shares of common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan.
• Indirect holdings include 8,280.258 shares by his spouse, 98,132 shares in a 401(k) plan, and 90 shares by his spouse as custodian for a child, with beneficial ownership disclaimed for spouse and child holdings.
• Mr. Lampropoulos also holds non-qualified stock options for a total of 212,719 shares across three grants with exercise prices of $37.71, $56.25, and $70.58.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling. The executive retains a significant stake, indicating continued alignment.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to recent events.
• The Executive Chairman retains a substantial direct beneficial ownership of 1,074,955 shares, demonstrating continued alignment with shareholder interests.
• Significant holdings of non-qualified stock options (212,719 shares) with exercise prices below the current sale price suggest potential for future gains and continued incentive.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.
• The sale of 5,000 shares represents a reduction in direct beneficial ownership by a key executive.

Future Outlook

The filing is a Form 4 and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It reflects a routine sale by a key executive within the medical devices sector, consistent with personal financial planning, especially given the Rule 10b5-1 plan.

Related Party Transactions

• The filing notes indirect beneficial ownership by the reporting person's spouse (8,280.258 shares) and spouse as custodian for a child (90 shares), though the reporting person expressly disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, might lead to minor concerns about insider sentiment, but the Rule 10b5-1 plan context generally alleviates significant negative interpretations. The executive's remaining substantial holdings suggest continued alignment.
• Employees, Customers, Suppliers, Creditors: This specific insider transaction is unlikely to have any direct or material impact on these stakeholders.

Key Dates

Recommendation

The Form 4 filing reports a routine, pre-scheduled insider sale by the Executive Chairman under a Rule 10b5-1 plan. While any insider sale warrants attention, the pre-planned nature and the executive's substantial remaining direct and indirect holdings (including significant options) suggest this is part of personal financial management rather than a signal of negative company prospects. Therefore, the filing itself does not provide a strong basis for a change in investment recommendation; a 'hold' stance is appropriate, pending further operational or financial news from Merit Medical Systems.

Keywords

Merit Medical Systems, MMSI, Fred P. Lampropoulos, Insider Trading, Form 4, Stock Sale, Executive Chairman, Beneficial Ownership, Rule 10b5-1, Medical Devices